Neuroinflammation pathway (not a molecule or receptor, but a biological process or network)

"Neuroinflammation pathways" refer to interconnected molecular and cellular processes in the CNS that govern inflammatory responses to stimuli such as trauma, infection, or neurodegeneration[2][4][6]. These pathways encompass the activation of glial cells (including microglia and astrocytes), release of pro-inflammatory and anti-inflammatory cytokines, chemokines, and the engagement of intracellular signal transduction cascades (for example, NF-κB, MAPK, JAK/STAT, PI3K–Akt, and others)[2][3][4]. Aberrant or chronic activation of these pathways underpins the pathogenesis of several neurodegenerative conditions, including Alzheimer's and Parkinson's diseases, multiple sclerosis, and neuropathic pain syndromes[2][3][4][6]. Therapeutic strategies frequently aim to inhibit key mediators within these pathways (e.g., cytokines, COX enzymes, signaling kinases), modulate the activity or phenotype of microglia, or prevent the recruitment of peripheral immune cells[1][2][3][6]. However, as neuroinflammation is a physiological defense and repair mechanism, broad inhibition carries the risk of interfering with essential CNS functions; fine-tuned, targeted intervention is thus a major challenge for drug development[2]. Because "Neuroinflammation pathways" is not a singular molecule, protein, or drug target but a set of interacting biological processes and signaling pathways, it is not suited to standard drug-target structured information frameworks. Most structured drug discovery efforts index individual pathway components or specific pathway nodes (e.g., “Tumor necrosis factor receptor 1,” “Mitogen-activated protein kinase p38,” “TREM2”), not the overall pathways themselves[2][3][4][6].

Other names

Neuroinflammatory signaling pathwayNeuroinflammation signaling cascadeNeuroimmune pathwayCNS inflammation pathways

Inhibition of proinflammatory cytokines (e.g., blocking TNF-α, IL-1β signaling); COX inhibition (reduce prostaglandin synthesis); Modulation of glial cell activity (e.g., microglia polarization, reduction of M1 pro-inflammatory state); Inhibition of MAPK/p38/JNK/NF-kappa B signal transduction